Ascites in Liver Cirrhosis with Ascitic Fluid Neutrophil Count >250 cells/mm³ and Signs of Developing Renal Impairment
This protocol addresses patients with liver cirrhosis and ascites in whom the ascitic fluid neutrophil count exceeds 250 cells/mm³ alongside evidence of developing renal impairment — specifically an increased or rising serum creatinine.
Liver cirrhosis with concurrent ascites, ascitic fluid neutrophil count confirmed above 250 cells/mm³, and signs of renal compromise reflected by an elevated or rising serum creatinine. This combination identifies a high-risk subgroup with both an infectious and a renal dimension requiring a coordinated approach.
Management in this setting involves empiric intravenous antibiotic therapy combined with intravenous albumin infusion. The albumin component is specifically warranted by the presence of renal impairment signs and is administered in two stages. The complete regimen, sequencing, and decision criteria are available in the full structured protocol.
A reduction in ascitic fluid neutrophil count of at least 25% of the pretreatment value after two days of treatment, with improvement in symptoms and signs, indicates a response to therapy.
References
DOI: 10.1136/gut.2006.099580
A recent study suggests that cefotaxime plus albumin improves survival and decreases the incidence of renal impairment to 10%.
Patients with SBP and signs of developing renal impairment should be given albumin at 1.5 g albumin/kg in the first six hours followed by 1 g/kg on day 3.
However, if patients have an increased serum creatinine or a rising serum creatinine, we would support infusing 1.5 g albumin/kg in the first six hours, followed by 1 g/kg on day 3, which is the regimen adopted by the Barcelona group in their study on the use of albumin in SBP.
A reduction in ascitic fluid neutrophil count of less than 25% of the pretreatment value after two days of antibiotic treatment suggests failure to respond to therapy.
Resolution of infection in SBP is associated with an improvement in symptoms and signs.
View source ↗